Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
Learn about the latest developments in the treatment of lung cancer, focusing on EGFR mutations, antibody-drug conjugates (ADCs), targeted therapies, and biomarker-driven approaches to improve patient outcomes in various stages of the disease.
CN-NSCLC-ATP-Seg05_ADCS
Video Player is loading.
EP: 1.Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies
EP: 2.Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
EP: 3.Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
EP: 4.EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data
Now Viewing
EP: 5.Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
EP: 6.EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
EP: 7.Unmet Needs in EGFR Exon 20 Insertion Non–Small Cell Lung Cancer
EP: 8.“Exciting Year” for Targeted Therapy Options for Mutated NSCLC, Experts Say
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
Transplant-Eligible, CAR T Considered: How Do We Decide?
The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
Personalizing CAR T: Making the Right Call for Each Patient
Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
Related Content
